Wortmannin

For research use only. Not for use in humans.

目录号:S2758 别名: KY 12420

Wortmannin Chemical Structure

Molecular Weight(MW): 428.43

Wortmannin是一种首次命名的PI3K抑制剂,在无细胞试验中IC50为3 nM,对 PI3K 家族的选择性较低。也会抑制自噬体的形成,并有效抑制DNA-PK/ATM,在无细胞试验中IC50为16 nM和150 nM。

规格 价格 库存 购买数量  
RMB 899.84 现货
RMB 1414.71 现货
RMB 2210.53 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Wortmannin发表文献109篇:

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述 Wortmannin是一种首次命名的PI3K抑制剂,在无细胞试验中IC50为3 nM,对 PI3K 家族的选择性较低。也会抑制自噬体的形成,并有效抑制DNA-PK/ATM,在无细胞试验中IC50为16 nM和150 nM。
靶点
PI3K [3]
(Cell-free assay)
DNA-PK [12]
(Cell-free assay)
ATM [12]
(Cell-free assay)
MLCK [1]
(Cell-free assay)
3 nM 16 nM 150 nM 170 nM
体外研究

钙或肽底物不影响Wortmannin对MLCK的抑制,但高浓度的ATP会减弱此种抑制。Wortmannin直接与MLCK催化结构域相互作用,导致不可逆转的酶活性减弱。Wortmannin对cAMP依赖蛋白激酶,cGMP依赖的蛋白激酶,钙调蛋白依赖激酶II,和蛋白激酶C均无抑制作用。[1] Wortmannin抑制由fMLP诱导的PtdInsP3(磷脂酰肌醇3,4,5-三磷酸化)形成,IC 50为5 nM 。在人中性粒细胞中,Wortmannin剂量为100 nM时可发挥完全抑制作用,增加PtdInsP2水平,且对PtdInsP和 PtdIns没有影响;Wortmannin可动态调控F-actin水平对fMLP刺激的肌动蛋白聚合无影响。[2]在RBL-2H3细胞中,Wortmannin通过结合110-kDa蛋白,不可逆的抑制磷酸肌醇3激酶(PI3-kinase)活性(IC 50为3 nM)对,对Pi4-kinase没有影响。Wortmannin也抑制Fc epsilon RI介导的组胺分泌和白三烯释放,对酪氨酸激酶Lyn无影响。[3]在大鼠脂肪细胞中,剂量为0.1 μM的 Wortmannin可完全抑制胰岛素诱导的己糖吸收,二不影响异丙肾上腺素刺激的脂肪分解活性。[4] 在人脐静脉内皮细胞中,在IGF-1的存在下,Wortmannin抑制胰岛素诱导一氧化氮生产,IC50为500nM。[5]在中国仓鼠卵巢细胞中, Wortmannin以50 μM剂量可抑制DNA双链断裂(DSB)修复,但对DSB水平无影响或单链断裂(SSB)酶活无影响。Wortmannin可加强电离辐射(红外)诱导的细胞毒作用,但本身无毒性。[6] Wortmannin抑制水球样激酶(PLK 1)活性,IC 50为24nM,造成细胞G 2 / M阻滞。[7] 在人巨噬细胞中,Wortmannin增加 Toll样受体(TLR)介导的白细胞介素- 6的积累,EC 50 = 50 nM。在小鼠巨噬细胞中,Wortmannin显着增强TLR诱导一氧化氮合酶(iNOS)的表达和亚硝酸盐积累。Wortmannin激活核因子-κB和上调细胞因子mRNA量。[8] Wortmannin也抑制水球样激酶(PlK)1和PlK 3,在有丝分裂中发挥重要作用。Wortmannin治疗可能导致可减少由DNA损伤诱导的p53丝氨酸20位磷酸化。[9] 在SW 1990细胞中,Wortmannin可抑制透明质酸诱导Akt磷酸化和细胞运动/迁移。[10]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A459 NEH5ZW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXNNk42KM7:TR?= NGPTZ2YyNTRiZB?= NGjkWW5FVVOR MWHlcohidmOnczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKHS{ZXH0cYVvfCC5aYToJJRidW:6aX\lci=> MVGyOVQ6ODN6Mx?=
H1703 NHzNOHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWqyMlUh|ryP NYfGSIdSOS12IHS= MUXEUXNQ MYLlcohidmOnczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKHS{ZXH0cYVvfCC5aYToJJRidW:6aX\lci=> MoXLNlU1QTB|OEO=
HUVECs MXvDfZRwfG:6aXPpeJkhSXO|YYm= NYf6botQOTByIH7N NXTpe5BmOjRiaB?= M2LzeoF1fGWwdXH0[ZMhfGinIHHido9o[XSrdnWg[YZn\WO2czDv[kBk[Wy7Y3;zbY4hd25iVmLJMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 M{C0UlI2PDVyMUi2
APRE-19 MoOwRZBweHSxc3nzJGF{e2G7 MljtOUDPxE1? NH7vRXUzPCCq M4PNV4Fjd2yrc3jld{BHVFpvbXXkbYF1\WRicILvMZN2en[rdnHsM4FvfGlvYYDvdJRwe2m|IHHjeIl3cXS7 NXPFepNiOjV|Mkm2NVc>
MDA-MB-231 NF;6OpFCeG:ydH;zbZMhSXO|YYm= NIDzXpEyyqEQvF5CpC=> MYC0PEBp NVrCdVB6TE2VTx?= NU\CbWl4\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKHS{ZXH0[YQhf2m2aDCyOUDPxE1ib3[gSlEhd3JiRkKgxsA> NFPKXW0zPTNyMEmzNi=>
MCF7 MlG4SpVv[3Srb36gRZN{[Xl? M1vxWVExOCCwTR?= M3\XOFI1KGh? MlrC[YxqdWmwYYTld{BGOi2rbnT1Z4VlKEGURT3MeYMh[WO2aY\peJk> MoHzNlUyPzJ3NUe=
HT-29  NWPMTZlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jsXFEvPcLiwsXN M3;qelk3KGh? M{n4ToRm[3KnYYPld{Bk\WyuIHfyc5d1cCC5aHnjbEBk[W5iYnWgbY5pcWKrdHXkJIJ6KEu\TlG= MYmyOVAyOjF{Mx?=
MO59K  M3zTcmN6fG:2b4jpZ4l1gSCDc4PhfS=> M2nXU|XDqM7:TR?= NGX4V|U4KGR? MlLkSG1UVw>? NUnVOoY2\W6qYX7j[ZMhfGinIHP5eI91d3irY3n0fUBw\iCndH;wc5Nq\GVib4KgZ4l{eGyjdHnu M2m4W|I1QTV|NU[x
MO59J Mn[yR5l1d3SxeHnjbZR6KEG|c3H5 M1rEWlXDqM7:TR?= NXfsZWpVPyCm M{nTO2ROW09? NFOydFRmdmijbnPld{B1cGViY4n0c5RwgGmlaYT5JI9nKGW2b4Dvd4ll\SCxcjDjbZNxdGG2aX6= MnPONlQ6PTN3NkG=
MO59K  Mnj6RZBweHSxc3nzJGF{e2G7 NGLMc5IyOCEQvF2= M1r4WFI1KGh? MWjEUXNQ NFribWxqdmO{ZXHz[ZMhfGinIFTTRkBt\X[nbDDpcoR2[2WmIHL5JIV1d3Cxc3nk[UBweiClaYPwcIF1cW5? NFfye4kzPDl3M{W2NS=>
MO59J M1L6e2Fxd3C2b4Ppd{BCe3OjeR?= M4jwcVExKM7:TR?= MonNNlQhcA>? NIPxeXhFVVOR MX\pcoNz\WG|ZYOgeIhmKESVQjDs[ZZmdCCrbnT1Z4VlKGK7IHX0c5Bwe2mmZTDvdkBkcXOybHH0bY4> Mm\ENlQ6PTN3NkG=
HepG2 Ml3iSpVv[3Srb36gRZN{[Xl? M4jPRlExOCCwTR?= M4fKWFAvPSCq NVTPT2h{TE2VTx?= MnfvZoxw[2u|IF3BMYlv\HWlZXSgRYt1KHCqb4PwbI9zgWyjdHnvci=> M4KxW|I1QDZ|M{Ww
A549  M2DTR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfhS3VnOyEEtV5CpC=> NFv3fYYzKGh? MXHzeZBxemW|c3XzJJBmdWW2cnX4[YQucW6mdXPl[EBCc3RiYX7kJGdUUzQQsjDhZ5RqfmG2aX;uMEBUNXCqYYPlJIFzemW|dDygZ4VtdCCjcH;weI9{cXNiYX7kJINie3Cjc3WtN{Bi[3SrdnH0bY9v NWTKcpNIOjR6NEe4OlM>
A549  MoHpSpVv[3Srb36gRZN{[Xl? NVu3eXhCOTEEoN88ceKh MoLMNVYhcA>? MYDEUXNQ M3\COI1w\HWuYYTld{B1cGViSVHWJJJmeGyrY3H0bY9vKGGwZDDjZZV{\XNicnX0[Y51cW:wIH;mJG5RKGmwIITo[UBvfWOuZYXzMi=> NXTDW4RVOjR6MEKxNVE>
SK-N-LO NET0fohHfW6ldHnvckBCe3OjeR?= MlqxNVAxKG6P NFTn[4UxNjViaB?= M{n4ZYRm[3KnYYPld{B1cGVic4TpcZVt[W62IHXm[oVkfHNib3[gcY9zeGirbnWgc44hSWu2IIDoc5NxcG:{eXzheIlwdg>? NXXydoVjOjR4NUS2NFY>
HL-60 M3nKcmZ2dmO2aX;uJGF{e2G7 MXmwMlHDqM7:TR?= M37wb|czKGh? NWrMOnd6[myxY3vzJIRie2G2aX7pZk1qdmS3Y3XkJINmdGxiZHnm[oVz\W62aXH0bY9v NVzXc3duOjR4MEeyO|M>
HepG2  MUjGeY5kfGmxbjDBd5NigQ>? M1\qSFIxOCCwTR?= NYjHeJNWOC53IHi= MXvheJRmdnWjdHXzJGZwgE9icHjvd5Bpd3K7bHH0bY9v NWnvfYJ2OjR3M{WxPVI>
H520 NUTG[ZdsTnWwY4Tpc44hSXO|YYm= MV:xNOKh|ryP NGP4OXQyKGh? NFHxfnRFVVOR M2q2SYRm[3KnYYPld{Bk\WyudXzhdkBxcG:|cHjvMWFMXCCycn;0[YlvKGyndnXsdy=> MonaNlQ1PDd7M{W=
H1975 MkH6SpVv[3Srb36gRZN{[Xl? M2C2OVExyqEQvF2= M4fBdlEhcA>? NHrIUotFVVOR MVzk[YNz\WG|ZYOgZ4VtdHWuYYKgdIhwe3Cqbz3BT3QheHKxdHXpckBt\X[nbIO= MlO2NlQ1PDd7M{W=
MG-63 MmCxRZBweHSxc3nzJGF{e2G7 NXjJbXNYOTBiwsXN MoG4NVIhcA>? M{\zUIVvcGGwY3XzJGRRNWmwZIXj[YQh[XCxcITvd4l{ MWKyOFM2QDNyMR?=
5637 NWGwWnZNSXCxcITvd4l{KEG|c3H5 MVexNOKh|ryP MkK5OFAhdWmw MnTNdoV3\XK|ZYOgdFIyX0GIMTDlfJBz\XO|aX;uMEBETEtiZYjwdoV{e2mxbjygZY5lKGOnbHygbY5pcWKrdHnvckBqdmS3Y3XkJIJ6KG[3Y3;p[IFv NEW2O4gzPDN|M{i2PC=>
HEK-293 M3uyfWZ2dmO2aX;uJGF{e2G7 NW\tS2N7OTVybl2= MV6xOkBp M13TT2ROW09? M3mzT4Rm[3KnYYPld{BEWlRiYXP0bZZqfHl? MnjKNlQ{OjR|Nk[=
SW480  M4WwSGZ2dmO2aX;uJGF{e2G7 M1XYS|E2OG6P NGjnV5UzOCCq NXv1RppWTE2VTx?= M{C0TpJm\HWlZYOgZ4VtdHWuYYKgZYNkfW23bHH0bY9vKG:oIN8yMYNifGWwaX6= NHTnd4EzPDN{NEO2Oi=>
HepG2 M4HLdGZ2dmO2aX;uJGF{e2G7 MVyxNFAhdk1? NV7mbGhZOjRiaB?= Mny2ZZR1\W63YYTld{B1cGViY3;sc45q\XNib3[geIhmKHS3bX;yJINmdGy|IIfpeIghfXC{ZXf1cIF1cW:wIH;mJGFsfDF? NYHn[4xqOjR{OUe1NVA>
HCT 116  NUH0fVZPTnWwY4Tpc44hSXO|YYm= MkTyNVAxKG6P Mm\aNlQhcA>? MXPheJRmdnWjdHXzJJRp\SClb3zvcolmeyCxZjD0bIUhfHWvb4KgZ4VtdHNid3n0bEB2eHKnZ4XsZZRqd25ib3[gRYt1OQ>? MkLQNlQzQTd3MUC=
BEL/FU Ml7JSpVv[3Srb36gRZN{[Xl? M1;SWlEhdU1? NYXGTpVDOjRiaB?= NFzrV41l\WO{ZXHz[ZMheHKxdHXpckBt\X[nbIOgc4YhfGinIGDJN2swSWu2IIDheIh4[Xl? NETJXIIzPDJ|MkC5PS=>
Huh7  Mom2SpVv[3Srb36gRZN{[Xl? NEjF[Y4{yqEQvF2= NGX5NmsyKGh? Mof6doVlfWOnczD0bIUhfmm{dYOg[Y51enliaX70c{B1cGViY3XscJM> M2G5eFI1OTh2MUm2
A-375 MU\BdI9xfG:|aYOgRZN{[Xl? MWC0M|gh|ryP M1PLNlI1KGh? M1nZOoVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= NHvNNIMzPDFzM{G3Ny=>
A-375-TS  MkGzRZBweHSxc3nzJGF{e2G7 NEDYbIs1NzhizszN M1TJdFI1KGh? M3vh[4VvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= MW[yOFEyOzF5Mx?=
Mel-HO MoH3RZBweHSxc3nzJGF{e2G7 M3W3OlQwQCEQvF2= M4f0[lI1KGh? NXjXS4Fy\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> NVy0Ro13OjRzMUOxO|M>
Mel-HO-TS M2LDU2Fxd3C2b4Ppd{BCe3OjeR?= MYW0M|gh|ryP MWGyOEBp NF7FcmRmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg NFXkRnozPDFzM{G3Ny=>
MeWo MX7BdI9xfG:|aYOgRZN{[Xl? NXLkNmNLPC96IN88US=> MofZNlQhcA>? NX\0V4h1\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> NIfTUHkzPDFzM{G3Ny=>
Mel-2a Mn\2RZBweHSxc3nzJGF{e2G7 NXGyOmIzPC96IN88US=> NWjiNI4xOjRiaB?= M{Tn[oVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= NYjjVnFLOjRzMUOxO|M>
MDA-MB-231 MX\GeY5kfGmxbjDBd5NigQ>? NEfsSoEx6oDVNECwJI5O M3rsUlQhcA>? MX3zeZBxemW|c3XzJGFsfCCyaH;zdIhwenmuYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NWKzRpc5OjJ7ME[yOVk>
MDA-MB-231 M37HZWZ2dmO2aX;uJGF{e2G7 NH;NSZg1ODBibl2= NGPpO2Y1KGh? MVvk[YNz\WG|ZYOgUW1RNTliYX7kJGlNNThicILveIVqdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MmnGNlI6ODZ{NUm=
Jurkat MlrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3SwUVAvOjVvMT6yOUDPxE1? MUGyOE81QCCq NWrwSJVmTE2VTx?= NH3RfVdqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT2g[IVx\W6mZX70JI1idm6nch?= MX2xPVc2PzF6NR?=
Namalwa NX7YPW5lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHWNE4zPS1zLkK1JO69VQ>? M3W5W|I1NzR6IHi= NYLkSoZDTE2VTx?= NGTieXdqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT2g[IVx\W6mZX70JI1idm6nch?= NWXIVHF5OTl5NUexPFU>
Jurkat Mn7ERZBweHSxc3nzJGF{e2G7 MnXENE4zPS1zLkK1JO69VQ>? MUmyOE81QCCq MkXKSG1UVw>? Mnv6bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMUBl\XCnbnTlcpQhdWGwbnXy NV3hTlJWOTl5NUexPFU>
Namalwa NWnkPJNJSXCxcITvd4l{KEG|c3H5 NVHtU5ljOC5{NT2xMlI2KM7:TR?= NY\xXmV6OjRxNEigbC=> M{j3eWROW09? M3:0Zolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCC2aX3lMUBidmRiZH;z[U0h\GWyZX7k[Y51KG2jbn7ldi=> M37WVlE6PzV5MUi1
K562 M{jld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHftPJAzPCCq MWfJR|UxRTJ3wsGwMlE1KG6P NIf4U|EyQTZ4MkO2NS=>
SW1990 MmTjSpVv[3Srb36gRZN{[Xl? MlO2NE4xOS1zIN88US=> M4jSUFEhcA>? MXvpcohq[mm2czDIRU1qdmS3Y3XkJGFsfCCyaH;zdIhwenmuYYTpc44> MmnqNVk1PjlyMkC=
RT112  M1XSZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3pNVDDqM7:TR?= MVOyOEBp NVHJc4NoTE2VTx?= NYH6dHU4\GWlcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKEd{L12gZ4VtdHN? NInnbm8yQDd6N{izNi=>
MHG-U1 NEHURWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV[xNOKh|ryP NGjFRYYzPCCq NWDpToFyTE2VTx?= M2nDboRm[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBIOi:PIHPlcIx{ MXGxPFc5Pzh|Mh?=
SMMC-7721 MVPBdI9xfG:|aYOgRZN{[Xl? Mk[0NlAxyqCwTR?= M17jdVI1KGh? MWnpcoNz\WG|ZYOgR2hZNWmwZIXj[YQh[XCxcITvd4l{ MUmxO|U2PzF7MR?=
SMMC-7721 MkToSpVv[3Srb36gRZN{[Xl? MUiyNFDDqG6P MoT1NlQhcA>? MXT1dE1z\We3bHH0[ZMh|rJzLETHWFEh\XiycnXzd4lwdg>? MXOxO|U2PzF7MR?=
HeLa MlHjSpVv[3Srb36gRZN{[Xl? M2m0OFExOMLibl5CpC=> NV;QT25FOSCq MVfhcJRmenNidHjlJI1wenCqb3zv[5khd2ZidHjlJJRz[W6|ZnXydolvKHKnY4njcIlv\yClb33wZZJ1dWWwdB?= NVPrVVNSOTZ6OUC5NVU>
MRC5VI MkPFSpVv[3Srb36gRZN{[Xl? NH\3UIYyOi53IH3N MXGwMlUhcA>? M2LqXWROW09? NWPiRYVl[WKxbHnzbIV{KHSqZTDT[ZI1PzNxVHjyN|A5yqCyaH;zdIhwenmuYYTpc44hd2ZiQXv0VGtDyqB? MUexOlIzPzN7NB?=
AT5BIVA MWHGeY5kfGmxbjDBd5NigQ>? MoTUNVIvPSCvTR?= NU[1NWw{OC53IHi= MlG5SG1UVw>? MmTWZYJwdGm|aHXzJJRp\SCVZYK0O|MwXGi{M{C4xsBxcG:|cHjvdplt[XSrb36gc4YhSWu2UFvCxsA> NGTE[nUyPjJ{N{O5OC=>
M059J M4XrXGZ2dmO2aX;uJGF{e2G7 Mkj5NVIvPSCvTR?= Mkn6NE42KGh? MWPEUXNQ NIjuWIFi[m:uaYPo[ZMhfGinIGPldlQ4Oy:WaIKzNFjDqHCqb4PwbI9zgWyjdHnvckBw\iCDa4TQT2LDqA>? M2ryZVE3OjJ5M{m0
HeLa NF;2eldHfW6ldHnvckBCe3OjeR?= NGT2cGkyOi53IH3N MViwMlUhcA>? MnK5SG1UVw>? MV;hZo9tcXOqZYOgeIhmKFOnckS3N{9VcHJ|MElCpJBpd3OyaH;yfYxifGmxbjDv[kBCc3SSS1NCpC=> Ml\jNVYzOjd|OUS=
N2a M1vBNGFxd3C2b4Ppd{BCe3OjeR?= MYWwMlEuOTBizszN M1\4RVIhcA>? MYfpcoR2[2W|IHTlZ5Jm[XOnZDDj[YxtKH[rYXLpcIl1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? MUKxOVg1Ojd4Nx?=
Jurkat  Mkf5T4lv[XOnIFHzd4F6 MWXJR|UxKG:oIEK0JI5O MUSxOVY3PDVzOR?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT / AKT / p-GSK3β / GSK3β / Bcl-xl / Bax / Caspase-3 / Cleaved caspase-3; 

PubMed: 25344912     


Four esophageal cancer cell lines were treated with different concentrations of wortmannin for 48 h, and cell lysates were collected for Western blot analysis of p-AKT, AKT, p-GSK3β, GSK3β, Bcl-xL, Bax, caspase-3, and cleaved caspase-3.

25344912
Immunofluorescence
DNMT1; 

PubMed: 24001151     


PC3 cells were treated with DMSO or wortmannin (1 μM) for 24 hours. DNMT1 and DNMT3B cellular localization was visualized by immunofluorescent staining. After 24h of treatment, cells were fixed in methanol, incubated with the indicated antibodies, stained with Alexa Fluor 594-tagged secondary antibodies and counterstained with DAPI. Slides were then mounted and examined under a fluorescence microscope. The bright field images of PC3 cells treated with DMSO or wortmannin (1 μM) for 24 hours are shown (right panel).

24001151
Growth inhibition assay
Cell viability; 

PubMed: 25344912     


MTT assay was used to determine the effects of different concentrations of wortmannin on viability of esophageal cancer cells lines KYSE150, HKESC-1, KYSE270, and T.Tn. Bars, SD; * P < 0.05; **, P < 0.01; ***, P < 0.001 compared with DMSO-treated cells.

25344912
体内研究 Wortmannin剂量为1mg/kg可抑移植瘤小鼠中SW1990的腹膜转移,无重量损失。[10] Wortmannin抑制在小鼠正常组织(肺,心脏和脑组织匀浆)及肿瘤组织中的phosphatidylinositide 3- B激酶(PKB)/磷酸化Akt,在剂量为0.7 mg/kg时无死亡或急性毒性。与gemcitabine联合使用时,可大大增加细胞凋亡和抑制原位肿瘤生长,两种药物单独使用都无以上效果。[11]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

动物实验:[11]
- 合并
  • Animal Models: 人胰腺癌细胞 PK1s.c.和原位注入SCID免疫缺陷小鼠。
  • Formulation: 0.4 mg/mL 溶于 DMSO, 使用时用 0.9% NaCl 稀释
  • Dosages: 0.175, 0.35, 和0.7 mg/kg
  • Administration: 静脉注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 85 mg/mL (198.39 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 428.43
化学式

C23H24O8

CAS号 19545-26-7
储存条件 粉状
溶于溶剂
别名 KY 12420

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品

Tags: 购买Wortmannin | Wortmannin供应商 | 采购Wortmannin | Wortmannin价格 | Wortmannin生产 | 订购Wortmannin | Wortmannin代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID